1992-1996 McGill University, Montreal, Canada; MDCM
1996-1999 Queens University / Kingston General & Hotel Dieu Hosptials, Kingston, Ontario; Internal Medicine
1989-1992 McGill University, Montreal Canada; BS
1999-2002 Hematology/Oncology Fellowship, Tufts University, Boston MA
2000-2002 Research Fellow, Tufts University School of Medicine, Boston, MA
2002-2005 Masters Degree in Epidemiology and Biostatistcs.
These include clinical research around adjuvant treatment options for patients with esophageal and stomach cancers, supportive care for patients undergoing abdominal radiation therapy including novel combinations of antiemetics in this setting (AVERT trial: NCT00970905), and the protective impact of lipid lowering agents called statins on the risk of venous blood clots in patients with advanced cancer. I also participate in many national cooperative group trials covering the cancer sites listed above.
Ades S. Adjuvant therapy for colon cancer in the elderly. Oncology 23(2):162-7, 2009
Ades S, Koushik A, Duarte-Franco E, Mansour N, Arseneau J, Provencher D, Gilbert L, Gotlieb W, Ferenczy A, Coutlée F, Roger M, Franco E (for the Biomarkers of Cervical Cancer Risk Study Team).Selected Class I and Class II HLA alleles and haplotypes and risk of high-grade cervical intraepithelial neoplasia. Int J Cancer 122(12):2820-6, 2008.L. E. Ferri*, S. Ades*, T. Alcindor, M.R. Chasen, V. Marcus, M. Hickeson, G. Artho, M. P. Thirlwell. Peri-Operative docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophageal and gastric adenocarcinoma: A Multi-Center Phase II Trial. Ann Oncol. 2011 Oct 29. (*Co-primary authorship Ferri & Ades) Epub ahead of print
Ades S, Maxfield LF, Gould CJ, Jones GK, Levy SB. Selection of non-P-glycoprotein mediated high-level etoposide resistant cell lines by adriamycin with P-gp inhibitors, Int J Oncol 28(3): 747-53, 2006
For a complete list of Steven Ades' publication, please visit Google Scholar